Donald E Cutlip1, Dean J Kereiakes2, Laura Mauri3, Robert Stoler4, Harold L Dauerman5. 1. Department of Medicine, Cardiology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: dcutlip@bidmc.harvard.edu. 2. The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati, Ohio. 3. Harvard Medical School, Boston, Massachusetts; Department of Medicine, Cardiology Division, Brigham and Women's Hospital, Boston, Massachusetts. 4. Baylor Heart and Vascular Institute, Baylor University Medical Center, Texas A&M Health Science Center, College of Medicine, Dallas, Texas. 5. Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont.
Abstract
OBJECTIVES: This study sought to assess the frequency and clinical impact of dual antiplatelet therapy (DAPT) nonadherence. BACKGROUND: There are limited data on the impact of DAPT nonadherence during the first year after a second-generation drug-eluting stent placement. METHODS: After successful Endeavor zotarolimus-eluting stent implantation, 2,265 patients were enrolled in a registry with limited exclusions and monitored during 12 months of prescribed DAPT. Predictors of any nonadherence (ANA) at 6 months were analyzed by multivariable analysis, and the association between ANA at 6 or 12 months with the endpoints of death, myocardial infarction, and stent thrombosis was assessed. RESULTS: The study population included 30% female patients, 34% with diabetes and 36% with acute coronary syndromes. ANA occurred in 208 patients (9.6%) before 6 months and 378 patients (18.5%) before 1 year. Major bleeding (odds ratio [OR]: 12.83, 95% confidence interval [CI]: 7.55 to 21.80, p < 0.001) was the only predictor of ANA at 6 months. In time-dependent analyses, ANA before 6 months was associated with an increased risk of death or myocardial infarction (7.6% vs. 3.0%, p < 0.001) and a numerical increase in stent thrombosis (2.0% vs. 0.9%, p = 0.12). After adjustment for baseline differences, ANA within 6 months remained associated with death or MI (OR: 1.95, 95% CI: 1.02 to 3.75). ANA occurring after 6 months did not increase the risk of subsequent ischemic events. CONCLUSIONS: DAPT ANA occurs frequently and is associated with increased risk for thrombotic complications if it occurs within the first 6 months. Major bleeding was a significant correlate of DAPT ANA within 6 months. (EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events; NCT01069003).
OBJECTIVES: This study sought to assess the frequency and clinical impact of dual antiplatelet therapy (DAPT) nonadherence. BACKGROUND: There are limited data on the impact of DAPT nonadherence during the first year after a second-generation drug-eluting stent placement. METHODS: After successful Endeavor zotarolimus-eluting stent implantation, 2,265 patients were enrolled in a registry with limited exclusions and monitored during 12 months of prescribed DAPT. Predictors of any nonadherence (ANA) at 6 months were analyzed by multivariable analysis, and the association between ANA at 6 or 12 months with the endpoints of death, myocardial infarction, and stent thrombosis was assessed. RESULTS: The study population included 30% female patients, 34% with diabetes and 36% with acute coronary syndromes. ANA occurred in 208 patients (9.6%) before 6 months and 378 patients (18.5%) before 1 year. Major bleeding (odds ratio [OR]: 12.83, 95% confidence interval [CI]: 7.55 to 21.80, p < 0.001) was the only predictor of ANA at 6 months. In time-dependent analyses, ANA before 6 months was associated with an increased risk of death or myocardial infarction (7.6% vs. 3.0%, p < 0.001) and a numerical increase in stent thrombosis (2.0% vs. 0.9%, p = 0.12). After adjustment for baseline differences, ANA within 6 months remained associated with death or MI (OR: 1.95, 95% CI: 1.02 to 3.75). ANA occurring after 6 months did not increase the risk of subsequent ischemic events. CONCLUSIONS:DAPT ANA occurs frequently and is associated with increased risk for thrombotic complications if it occurs within the first 6 months. Major bleeding was a significant correlate of DAPT ANA within 6 months. (EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events; NCT01069003).
Authors: Konstantinos C Koskinas; Thomas Zanchin; Roland Klingenberg; Baris Gencer; Fabrice Temperli; Andreas Baumbach; Marco Roffi; Aris Moschovitis; Oliver Muller; David Tüller; Stefan Stortecky; Francois Mach; Thomas F Lüscher; Christian M Matter; Thomas Pilgrim; Dik Heg; Stephan Windecker; Lorenz Räber Journal: J Am Heart Assoc Date: 2018-04-13 Impact factor: 5.501
Authors: Scott Kinlay; Lien Quach; Jean Cormack; Natalie Morgenstern; Ying Hou; Melissa Young; Rebecca Sherrod; Kelly Cho; David P Faxon; Ronnie Ramadan; Michael Gaziano; David Gagnon Journal: J Am Heart Assoc Date: 2021-04-26 Impact factor: 6.106
Authors: P Michael Ho; Colin I O'Donnell; Marina McCreight; Anthony A Bavry; Hayden B Bosworth; Saket Girotra; P Michael Grossman; Christian Helfrich; Faisal Latif; David Lu; Michael Matheny; Kreton Mavromatis; Jose Ortiz; Amitabh Parashar; Devona M Ratliff; Gary K Grunwald; Michael Gillette; Hani Jneid Journal: J Am Heart Assoc Date: 2022-06-29 Impact factor: 6.106
Authors: Valentina Forni Ogna; Isabelle Bassi; Isabelle Menetrey; Olivier Muller; Eric Tousset; Pierre Fontana; Eric Eeckhout; Chin B Eap; Bernard Vrijens; Michel Burnier; Grégoire Wuerzner Journal: Front Pharmacol Date: 2017-10-25 Impact factor: 5.810